BiotechTube

Biktarvy 50Mg-200Mg-25Mg Tablet

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Harm Reduction

Conditions

Harm Reduction, HIV Infections, Drug Use

Trial Timeline

Mar 4, 2021 → Dec 31, 2023

NCT ID
NCT04650269

About Biktarvy 50Mg-200Mg-25Mg Tablet

Biktarvy 50Mg-200Mg-25Mg Tablet is a approved stage product being developed by Gilead Sciences for Harm Reduction. The current trial status is completed. This product is registered under clinical trial identifier NCT04650269. Target conditions include Harm Reduction, HIV Infections, Drug Use.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT04944654ApprovedTerminated
NCT04650269ApprovedCompleted

Competing Products

20 competing products in Harm Reduction

See all competitors
ProductCompanyStageHype Score
GP30341 capsules 200 mg + Standard therapyGEROPHARMPre-clinical
15
GP40221 + ozempicGEROPHARMPhase 1
25
GP40141 + NplateGEROPHARMPhase 1
25
Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mgGEROPHARMPhase 1
25
Rinsulin NPH + Humulin NPHGEROPHARMPre-clinical
15
Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)YuhanPhase 1
33
DS-8500a + ItraconazoleDaiichi SankyoPhase 1
33
Milademetan + Itraconazole + PosaconazoleDaiichi SankyoPhase 1
33
Pexidartinib + ProbenecidDaiichi SankyoPhase 1
33
DS-8500a + RosuvastatinDaiichi SankyoPhase 1
33
DS-8500aDaiichi SankyoPhase 1
33
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment CDaiichi SankyoPhase 1
33
tolterodine + mirabegronAstellas PharmaApproved
85
ASP3652Astellas PharmaPhase 1
33
ASP015K ER + ASP015K IRAstellas PharmaPhase 1
33
YM178 modified release (OCAS) + YM178 immediate release (IR)Astellas PharmaPhase 1
33
Isavuconazole + dextromethorphanAstellas PharmaPhase 1
33
mirabegron + metoprololAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
zolbetuximab + oxaliplatin + leucovorin + fluorouracil + Pembrolizumab + folinic acid + nivolumab + DocetaxelAstellas PharmaPhase 2
52

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved
84
Truvada + Atazanavir + RitonavirApproved
84
Truvada + efavirenzApproved
84
B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved
84
TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved
84